Patrick NJ Schnegelsberg elected to AZBio board

Picard Medical, Inc. announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of Directors of the Arizona Bioindustry Association (AZBio), the state affiliate in Arizona of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies His term serving on the board will extend through December 2028.

“Arizona has long been an important hub for life sciences innovation, and AZBio plays a critical role in fostering collaboration and growth across our industry,” said Patrick NJ Schnegelsberg, CEO of Picard Medical and SynCardia Systems. “SynCardia has deep roots in Arizona, and I am honored to join the AZBio Board to help strengthen the states bioscience ecosystem and advance lifesaving medical technologies for patients.”

“We are thrilled to welcome Patrick NJ Schnegelsberg to the AZBio Board of Directors,” commented Joan Koerber-Walker, President and CEO of the Arizona Bioindustry Association, Inc. “For over two decades, SynCardia has been at the heart of Arizona’s MedTech sector, driving innovation, creating opportunity, and saving lives. By sharing his deep experience vested in this area and dedication to driving health innovation forward, Patrick joins a statewide community of leaders who support Arizona’s health innovators as they work to improve the lives of patients on a global basis.”

Schnegelsberg has extensive leadership experience at the intersection of advanced medical technology, clinical care, and commercialization. SynCardia, headquartered in Tucson for more than two decades, is the developer of the world’s first and only commercially available total artificial heart approved by both the US FDA and Health Canada.

Through this appointment, Picard Medical further reinforces its long-standing commitment to Arizona’s life sciences community and to advancing innovations that improve and extend patients’ lives.
MB Bureau